Reperfusion Treatment Market, by Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulphide Treatment, and Others), by Injury Type (Heart Injury, Kidney Injury, Intestine Injury, and Others), by Distribution Channel (Hospit

Reperfusion Treatment Market, by Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulphide Treatment, and Others), by Injury Type (Heart Injury, Kidney Injury, Intestine Injury, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Reperfusion therapy is used to restore the blood flow in blocked arteries after a heart attack. Reperfusion injury is usually developed due injury to organs during transplantation and others. Patients are treated using anti-platelet therapy, open or endovascular revascularization, coronary angioplasty, and others. Reperfusion injury can occur in organs such as heart, kidney, liver, intestine, lungs, and brain. Currently, clinical trials are being conducted for medicines for the treatment of reperfusion injury.
Market Dynamics
Market players are focusing on various inorganic growth strategies such as mergers and collaborations to strengthen their position in the global market. This is expected to drive the growth of the global reperfusion treatment market during the forecast period. In January 2018, Perfusion.com, Inc. and HEME Perfusion, Inc., providers of outsourced perfusion services, announced their merger. Under this merger agreement, the companies combined their business operations in 2021 and currently operate under the Perfusion.com brand.
Market players are focusing on conducting preclinical trials for a lead product candidate molecule to test the safety and effectiveness of the product in animals. For instance, in 2021, Ischemix conducted preclinical trials for studying the effects of its lead product candidate molecule, CMX-2043, in the treatment of traumatic brain injury. The trials showed positive results by decreasing mitochondrial reactive oxygen species and increasing mitochondrial bioenergetics. Therefore, the lead product reduces the injuries induced by reactive oxygen species in the brain of the animals. Furthermore, the company is planning to carry out phase I trials for the traumatic brain injury in humans.
Key features of the study:
This report provides in-depth analysis of the global reperfusion treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global reperfusion treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study are Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V., Balmes Transplantation SAS, Revive Therapeutics Ltd., Faraday Pharmaceuticals, Radikal Therapeutics Inc., Amyndas Pharmaceuticals, Perfusion.com, Inc., Angion Biomedica Corp., Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc., and Bolder Bio Technology Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global reperfusion treatment market report caters to various stakeholders in this industry including investors, suppliers, reperfusion therapy manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global reperfusion treatment market.

Detailed Segmentation
Global Reperfusion Treatment Market, By Treatment Type,
Therapeutic Hypothermia
Cyclosporin
Stem Cell Therapy
Hydrogen Sulphide Treatment
Others
Global Reperfusion Treatment Market, By Injury Type,
Heart Injury
Kidney Injury
Intestine Injury
Others
Global Reperfusion Treatment Market, By Distribution Channel,
Hospital Pharmacies
Retail Pharmacies
Others
Global Reperfusion Treatment Market, By Region,
North America
By Country
U.S.
Canada
By Treatment Type
Therapeutic Hypothermia
Cyclosporin
Stem Cell Therapy
Hydrogen Sulphide Treatment
Others
By Injury Type
Heart Injury
Kidney Injury
Intestine Injury
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Treatment Type
Therapeutic Hypothermia
Cyclosporin
Stem Cell Therapy
Hydrogen Sulphide Treatment
Others
By Injury Type
Heart Injury
Kidney Injury
Intestine Injury
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Treatment Type
Therapeutic Hypothermia
Cyclosporin
Stem Cell Therapy
Hydrogen Sulphide Treatment
Others
By Injury Type
Heart Injury
Kidney Injury
Intestine Injury
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Treatment Type
Therapeutic Hypothermia
Cyclosporin
Stem Cell Therapy
Hydrogen Sulphide Treatment
Others
By Injury Type
Heart Injury
Kidney Injury
Intestine Injury
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Treatment Type
Therapeutic Hypothermia
Cyclosporin
Stem Cell Therapy
Hydrogen Sulphide Treatment
Others
By Injury Type
Heart Injury
Kidney Injury
Intestine Injury
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Treatment Type
Therapeutic Hypothermia
Cyclosporin
Stem Cell Therapy
Hydrogen Sulphide Treatment
Others
By Injury Type
Heart Injury
Kidney Injury
Intestine Injury
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Company Profiles
Corline Biomedical AB*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
SBI Holdings Inc.
Pharming Group NV
Mallinckrodt Pharmaceuticals
MIFCOR, Inc.
CFM Pharma Holding B.V.
Balmes Transplantation SAS
Revive Therapeutics Ltd.
Faraday Pharmaceuticals
Radikal Therapeutics Inc.
Amyndas Pharmaceuticals
Perfusion.com, Inc.
Angion Biomedica Corp.
Young Therapeutics, LLC
Ischemix
Stealth Biotherapeutics Inc.
Bolder Bio Technology Inc.
“*” marked represents similar segmentation in other categories in the respective section.